United States: Capitol Hill Healthcare Update - April 2018

CONGRESS RECONVENES, WITH A FOCUS ON OPIOIDS

Lawmakers return today to Capitol Hill after a two-week recess, and multiple committees in both the House and Senate are poised to examine the opioid crisis and potential legislative solutions.

The Senate HELP Committee will hold a hearing Wednesday on bipartisan legislation that, among other things, would give the Food and Drug Administration (FDA) and National Institutes of Health (NIH) flexibility to promote alternative pain treatments, allow nurse practitioners and physician assistants to prescribe medication-assisted treatments, and establish uniform guidelines for local opioid recovery centers.

Other opioid-related hearings Wednesday include a Senate Judiciary subcommittee hearing on fentanyl and a House Oversight and Government Reform healthcare subcommittee hearing on local responses to the epidemic. Separately, leaders on the Senate Finance Committee are soliciting their members for opioid-related legislative proposals to include in a potential bill.

The House Energy and Commerce health subcommittee will also hold a hearing Wednesday on a series of opioid bills. Among the legislation under consideration are measures requiring state Medicaid programs to use prescription drug-monitoring programs, mandating e-prescribing for Medicare coverage of controlled substances under Part D and standardizing electronic prior authorizations for controlled substances under Part D.

Congressional attention on opioids isn't expected to dissipate anytime soon. The House Energy and Commerce investigations subcommittee will hold a hearing in early May that will include the CEOs of the nation's largest pharmaceutical distributors.

PRESCRIPTION DRUGS, MEDICAL DEVICES CAUGHT UP IN CHINA TARIFF DEBATE

The House Ways and Means Committee will hold a hearing Thursday to examine the impact of the Trump administration's proposed tariffs on Chinese imports, which would impact the pharmaceutical and medical technology industries.

Raw drug ingredients and technologies used in medical devices are among the 1,300 products on which Trump is proposing to levy a new 25 percent tariff. Of the $50 billion in Chinese imports the White House targeted for tariffs, more than 10 percent include pharmaceutical and medical device products.

The proposed tariffs target pacemakers, artificial joints, MRI machines and sterile equipment used in surgeries. The FDA said 80 percent of the raw ingredients in the prescription drugs used by U.S. patients are imported from either China or India.

Industry representatives for both the drug and device sectors will lobby lawmakers and the Office of the U.S. Trade Representative to try to remove key healthcare-related imports from the list of proposed tariffs.

JOHNSON WANTS HOUSE TO VOTE ON HIS 'RIGHT TO TRY' LEGISLATION

The author of Senate-passed legislation that would give terminally ill patients wider access to unapproved prescription drugs is calling on House leaders to schedule a vote on his bill.

Sen. Ron Johnson (R-Wis.) last week said the easiest path to enact his so-called right-to-try legislation is for the House to approve his bill rather than pushing an alternative measure. House leaders have so far been noncommittal on next steps on the issue.

Last month, House leaders negotiated a compromise bill that differed slightly from Johnson's legislation, which the Senate approved on a voice vote last year. That House bill, which won approval 267-149, would create a pathway for terminally ill patients to request access to unapproved treatments directly from pharmaceutical manufacturers.

Although only two House Republicans voted against the House bill in March, GOP leaders have been cool to the underlying idea, saying the FDA's existing compassionate-use program provides patients with access to treatments that have yet to win agency approval.

Both Johnson's bill and the House-approved measure would apply only to prescription drugs, not medical devices.

LAWMAKERS TO QUESTION COLLINS ON NIH BUDGET

A House appropriations subcommittee on Wednesday will hear testimony from NIH Director Francis Collins on his agency's fiscal 2019 budget.

President Trump earlier this year proposed NIH receive $35.5 billion, a $500 million increase after proposing cutting its budget the year before. But lawmakers last month already boosted NIH spending to $37.1 billion for the current fiscal year, with the added money targeting Alzheimer's disease research, opioids and a universal flu vaccine.

Fiscal 2019 begins Oct. 1.

KEY DEMOCRAT CRITICIZES CMS FOR NOT UPDATING DRUG PAYMENTS DATABASE

The top Democrat on the House Energy and Commerce Committee last week criticized Center for Medicare and Medicaid Services (CMS) for not updating a database that tracks Medicare and Medicaid spending on prescription drugs.

In a letter to CMS administrator Seema Verma, Rep. Frank Pallone (D-N.J.) said the agency's prescription drug dashboard is a key tool to track taxpayer spending on drugs, but that CMS hasn't added new data since the Trump administration came into office last year. Not updating the database "raises questions about this administration's supposed commitment to lowering the price of prescription drugs for the American people," Pallone wrote.

He asked Verma to respond to a series of questions, including justifying why the database hasn't been updated and whether CMS staffers were instructed not to update it.

GAO CALLS ON CMS TO STRENGTHEN MEDICARE DATA SECURITY 

The House Energy and Commerce Committee last week released a report from Congress' watchdog agency that called for greater oversight by CMS over Medicare data security.

The report by the Government Accountability Office (GAO) noted that CMS had created an oversight program for data obtained by Medicare administrative contractors, but the agency hadn't established a similar program to monitor security implementation by other entities, including researchers.

The GAO recommended CMS provide additional guidance on required security controls and that CMS more routinely track oversight efforts.

The committee's oversight panel has held several hearings in recent months to examine policy solutions to strengthen cybersecurity efforts in the healthcare sector.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions